JP2007504242A - マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法 - Google Patents

マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法 Download PDF

Info

Publication number
JP2007504242A
JP2007504242A JP2006525453A JP2006525453A JP2007504242A JP 2007504242 A JP2007504242 A JP 2007504242A JP 2006525453 A JP2006525453 A JP 2006525453A JP 2006525453 A JP2006525453 A JP 2006525453A JP 2007504242 A JP2007504242 A JP 2007504242A
Authority
JP
Japan
Prior art keywords
mmol
diagnostic
patient
compound
dimethylformamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504242A5 (https=
Inventor
トーマス・ディ・ハリス
パドマジャ・ヤラマンチリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of JP2007504242A publication Critical patent/JP2007504242A/ja
Publication of JP2007504242A5 publication Critical patent/JP2007504242A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006525453A 2003-09-03 2004-09-02 マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法 Pending JP2007504242A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49996603P 2003-09-03 2003-09-03
US49996003P 2003-09-03 2003-09-03
PCT/US2004/028660 WO2005023314A1 (en) 2003-09-03 2004-09-02 Compounds containing matrix metalloproteinase substrates and methods of their use

Publications (2)

Publication Number Publication Date
JP2007504242A true JP2007504242A (ja) 2007-03-01
JP2007504242A5 JP2007504242A5 (https=) 2007-04-12

Family

ID=34278690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525453A Pending JP2007504242A (ja) 2003-09-03 2004-09-02 マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法

Country Status (6)

Country Link
US (1) US20050106100A1 (https=)
EP (1) EP1691845A4 (https=)
JP (1) JP2007504242A (https=)
AU (1) AU2004270200A1 (https=)
CA (1) CA2537771A1 (https=)
WO (1) WO2005023314A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523327A (ja) * 2019-02-01 2022-04-22 グリンプス バイオ， インコーポレイテッド 細胞、細胞外マトリックスおよび組織微小環境における構造的再構築の検出

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2644694C (en) * 2006-03-10 2014-05-13 Sangeeta N. Bhatia Triggered self-assembly conjugates and nanosystems
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2648385C (en) 2006-04-04 2020-09-01 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
WO2009007846A2 (en) * 2007-06-15 2009-01-15 Universitetet If Oslo Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009029936A1 (en) * 2007-08-31 2009-03-05 Case Western Reserve University In vivo imaging of myelin
US8361438B2 (en) 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
CA2803520C (en) 2009-07-08 2019-10-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
BR112012008063A2 (pt) * 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
RU2607041C2 (ru) * 2015-05-29 2017-01-10 Общество с ограниченной ответственностью "Научно-производственная фирма ДНК-Технология" Способ определения степени гноетечения на пародонте по уровню мРНК гена интерлейкина-8 (IL-8) человека
WO2018148596A1 (en) * 2017-02-10 2018-08-16 Boston Scientific Scimed, Inc. Vascular ulcer treatment
EP3774838B9 (en) 2018-04-10 2025-12-10 Sanofi-Aventis Deutschland GmbH Lixisenatide synthesis with capping
IN202021002695A (https=) * 2020-01-21 2021-07-23
JP2023550412A (ja) * 2020-11-19 2023-12-01 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
WO2025085511A1 (en) * 2023-10-18 2025-04-24 University Of Washington Systems and methods for polymer-mediated activation of engineered cells

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859777A (en) * 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4452774A (en) * 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents
EP0247156B1 (en) * 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
CA1305160C (en) * 1985-12-23 1992-07-14 Paul Louis Bergstein Ether isonitriles and radiolabeled complexes thereof
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5252317A (en) * 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5064956A (en) * 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
EP0577675B1 (en) * 1991-03-27 1999-12-08 Nycomed Salutar Inc. Contrast media
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
US5744120A (en) * 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
EP0692978A4 (en) * 1993-03-31 1998-05-06 Mallinckrodt Medical Inc RADIOPHARMACEUTICAL PREPARATIONS THAT DO NOT CONTAIN TIN REDUCER
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
SE515621C2 (sv) * 1995-05-08 2001-09-10 Ericsson Telefon Ab L M Förfarande vid lägesbestämning
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
IT1275571B (it) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
AU726914B2 (en) * 1996-04-01 2000-11-23 Epix Pharmaceuticals, Inc. Bioactivated diagnostic imaging contrast agents
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6083486A (en) * 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US5980863A (en) * 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US6254852B1 (en) * 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
WO2002072014A2 (en) * 2001-03-08 2002-09-19 Volcano Therapeutics, Inc. Medical devices, compositions and methods for treating vulnerable plaque

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523327A (ja) * 2019-02-01 2022-04-22 グリンプス バイオ， インコーポレイテッド 細胞、細胞外マトリックスおよび組織微小環境における構造的再構築の検出

Also Published As

Publication number Publication date
AU2004270200A1 (en) 2005-03-17
EP1691845A1 (en) 2006-08-23
WO2005023314A1 (en) 2005-03-17
US20050106100A1 (en) 2005-05-19
CA2537771A1 (en) 2005-03-17
EP1691845A4 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
JP2007504242A (ja) マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法
US7060248B2 (en) Matrix metalloproteinase inhibitors
AU2001238319A1 (en) Matrix metalloproteinase inhibitors
JP7584426B2 (ja) 改善された組織特異性を有する前立腺特異的膜抗原（ｐｓｍａ）リガンド
JP2004537573A (ja) 心臓灌流およびビトロネクチン受容体を標的とするイメージング剤の同時イメージング
US20070014721A1 (en) Hydrazide conjugates as imaging agents
US6989139B2 (en) Matrix metalloproteinase inhibitors
JP6087386B2 (ja) 造影剤としてのｎ−アルコキシアミド抱合体
JP4878119B2 (ja) エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ニトロベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
CN1874792A (zh) 包含基质金属蛋白酶底物的化合物及其使用方法
US20120064002A1 (en) Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents
MXPA06002312A (en) Compounds containing matrix metalloproteinase substrates and methods of their use
JP5162081B2 (ja) エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸と生体分子との結合体、その塩の製造方法並びに医薬品の製造のためのそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091117